Advertisement

PharmacoEconomics

, Volume 31, Issue 10, pp 909–918 | Cite as

Cost-Effectiveness of Rivaroxaban Versus Warfarin for Stroke Prevention in Atrial Fibrillation in the Belgian Healthcare Setting

  • Joris Kleintjens
  • Xiao Li
  • Steven Simoens
  • Vincent Thijs
  • Marnix Goethals
  • Ernst R. Rietzschel
  • Yumi Asukai
  • Ömer Saka
  • Thomas Evers
  • Petra Faes
  • Stefaan Vansieleghem
  • Mimi De Ruyck
Open Access
Original Research Article

Abstract

Background

Warfarin, an inexpensive drug that has been available for over half a century, has been the mainstay of anticoagulant therapy for stroke prevention in patients with atrial fibrillation (AF). Recently, rivaroxaban, a novel oral anticoagulant (NOAC) which offers some distinct advantages over warfarin, the standard of care in a world without NOACs, has been introduced and is now recommended by international guidelines.

Objective

The aim of this study was to evaluate, from a Belgian healthcare payer perspective, the cost-effectiveness of rivaroxaban versus use of warfarin for the treatment of patients with non-valvular AF at moderate to high risk.

Methods

A Markov model was designed and populated with local cost estimates, safety-on-treatment clinical results from the pivotal phase III ROCKET AF trial and utility values obtained from the literature.

Results

Rivaroxaban treatment was associated with fewer ischemic strokes and systemic embolisms (0.308 vs. 0.321 events), intracranial bleeds (0.048 vs. 0.063), and myocardial infarctions (0.082 vs. 0.095) per patient compared with warfarin. Over a lifetime time horizon, rivaroxaban led to a reduction of 0.042 life-threatening events per patient, and increases of 0.111 life-years and 0.094 quality-adjusted life-years (QALYs) versus warfarin treatment. This resulted in an incremental cost-effectiveness ratio of €8,809 per QALY or €7,493 per life-year gained. These results are based on valuated data from 2010. Sensitivity analysis indicated that these results were robust and that rivaroxaban is cost-effective compared with warfarin in 87 % of cases should a willingness-to-pay threshold of €35,000/QALY gained be considered.

Conclusions

The present analysis suggests that rivaroxaban is a cost-effective alternative to warfarin therapy for the prevention of stroke in patients with AF in the Belgian healthcare setting.

Keywords

Atrial Fibrillation Warfarin International Normalize Ratio Dabigatran Rivaroxaban 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Key Points for Decision Makers

• A large proportion of patients with atrial fibrillation (AF) and moderate to high risk of stroke do not receive thromboprophylaxis or are not optimally controlled with vitamin K antagonists (VKAs).

• Rivaroxaban (Xarelto®), a once-daily agent, is one of the novel oral anticoagulants that are now recommended by recent international guidelines as broadly preferable to VKAs for patients with non-valvular AF.

• The present analysis suggests that rivaroxaban is a cost-effective alternative to warfarin therapy for the prevention of stroke in patients with AF in the Belgian healthcare setting.

1 Introduction

Atrial fibrillation (AF) is associated with an increase in the risk of ischemic stroke by a factor of four to five and accounts for 15–25 % of all stroke cases [1, 2]. Stroke is a major cause of long-term disability and death. According to the WHO, in 2004, stroke and other cerebrovascular diseases accounted for 5.7 million deaths worldwide (9.7 % of total) and was the second leading cause of death after coronary heart disease [3, 4]. In Belgium, the gender- and age-adjusted incidence rate for first-ever and recurrent stroke is estimated to be 185 per 100,000 inhabitants per year [5]. Given that about one-fifth of all stroke cases are attributable to AF [6], it is thought that AF causes 4,000 stroke cases per year in Belgium.

An individual’s risk of AF-related stroke can be estimated with CHADS2 scores (scale ranging from 0 to 6, with a greater risk of stroke indicated by higher scores) and reduced by two-thirds with effective anticoagulation. Vitamin K antagonists (VKAs), such as warfarin, have been the mainstay of anticoagulant therapy for over half a century [7]. In Belgium, most AF patients with moderate to high risk of stroke (CHADS2 score ≥2) are currently treated with VKA therapy (±50 % of patients) or aspirin (±25 %), or receive other non-pharmacological treatments [8, 9]. There are, however, some disadvantages associated with VKA therapy. These agents have a slow onset of action and possess a narrow therapeutic window. Due to pharmacogenetic variability and the various interactions VKAs have with both food and other drugs, it tends to be difficult to maintain a patient within the optimal international normalized ratio (INR) range of 2.0–3.0. As a result, there is a need for frequent and lifelong blood monitoring [10].

Recently, novel oral anticoagulants (NOACs), rivaroxaban (once daily), dabigatran etexilate (twice daily), apixaban (twice daily) have been approved as possible alternatives to VKA therapy. Rivaroxaban (Xarelto®) is a highly selective, oral, once daily, direct factor Xa inhibitor that has shown a favourable risk-benefit profile compared with warfarin in the prevention of stroke and systemic embolism events. In the phase III study (ROCKET AF), rivaroxaban demonstrated a 21 % risk reduction in event rate for stroke and systemic embolism (hazard ratio [HR] 0.79; 95 % CI 0.66–0.96; p < 0.001 for non-inferiority) while on-treatment compared with warfarin, and a significant reduction in the most serious complications of warfarin therapy, i.e. intracranial haemorrhage and fatal bleeding [11]. Since then the product has been approved for stroke prevention in non-valvular AF by both the US FDA and the European Medicines Agency (EMA), and in many countries worldwide. Dabigatran etexilate and apixaban also showed a favourable risk-benefit profile compared with warfarin in their phase III trials (RE-LY and ARISTOTLE, respectively) [12, 13]. On the basis of the clinical evidence that has arisen in the last few years, the most recent version of the European Society of Cardiology guidelines for the management of AF now recommends the NOACs as broadly preferable to VKAs in the vast majority of patients with non-valvular AF, when used as studied in the clinical trials [14].

Warfarin therapy is both effective and inexpensive, but treatment with rivaroxaban offers some distinct advantages over warfarin. Therefore, the aim of the present study was to evaluate the cost-effectiveness of rivaroxaban versus warfarin for the prevention of stroke in patients with AF at moderate (CHADS2 score = 2) to high risk (CHADS2 score >2) in the Belgian healthcare setting. To our knowledge, this is one of the very first studies evaluating this hypothesis.

2 Methods

2.1 Model Structure

For this study, a Markov cost-effectiveness model was designed that can be used by decision makers to systematically assess the comparative costs and outcomes of a new treatment compared with warfarin (Fig. 1). Patients with a mean age of 73 years and suffering from non-valvular AF at moderate (CHADS2 score = 2) to high risk of stroke (CHADS2 score = 3 or higher) enter the model and receive chronic treatment with either rivaroxaban (new treatment, 15–20 mg oral tablet, once daily) or dose-adjusted warfarin (comparator treatment, target INR of 2.5). In both cases, patients received aspirin after discontinuation of the initial treatment. The evaluation was carried out from the perspective of the Belgian health care payer (i.e. National Institute for Health and Disability Insurance and patients).
Fig. 1

Structure of the model. Afib atrial fibrillation, IC intracranial, MI myocardial infarction, Tx treatment

The model was populated with clinical data from the pivotal head-to-head phase III ROCKET AF trial and local cost estimates in order to calculate an incremental cost-effectiveness ratio (ICER) of rivaroxaban compared with warfarin. Direct comparisons with dabigatran or apixaban were not done as head-to-head trials do not exist and both molecules were not yet approved at the time of the ROCKET trial. The cycle length of the model was 3 months and patients progressed between states according to the event rates as observed in the trial. Patients experiencing an ischemic stroke were presumed to continue with their anticoagulation therapy if they were already on therapy and/or to (re)-initiate the therapy if they had discontinued. Modified Rankin Scores (mRS), a commonly used scale for measuring the degree of disability or dependence in the daily activities, were recorded in the ROCKET AF trial and used to categorize strokes as either minor (mRS score 0–2) or major (mRS score 3–5). In the post-stroke, post-myocardial infarction and post-intracranial bleed states, patients continued to be at risk of experiencing secondary events according to the risk profile of the drug they had been re-initiated on. These secondary events are minor bleeds, major extracranial bleed, myocardial infarction and systemic embolisms. The patients will not be sent to the respective secondary health states but instead will be given a pay-off corresponding to the cost and (dis)utility of those acute events. If the utility of the secondary event is higher than the utility of the primary health state, the utility from the primary health state will be applied. This is to prevent the eventual return of these patients to a less severe health state (e.g. from post-stroke to stable AF) where the utility and cost consequences of the more severe health states would not be applied. The main complications, classified as either transient (non-boxed states in Fig. 1) or permanent (boxed) health states, were death, ischemic stroke, systemic embolism, bleeding and myocardial infarction. Bleeding events were categorized as major extracranial, clinically relevant non-major (CRNM) extracranial, and intracranial as defined in the manuscript describing the rationale and design of the ROCKET AF study [15].

2.2 Clinical Effectiveness and Treatment Discontinuation

The main clinical data inputs were based on the safety on treatment results of the ROCKET AF trial and are presented in Table 1. ROCKET AF was found to be the only single trial that provides head-to-head clinical evidence on efficacy and safety of rivaroxaban in stroke prevention in AF compared with adjusted-dose warfarin. Rivaroxaban was associated with significant reductions in intracranial haemorrhage (0.5 vs. 0.7 %; p = 0.02) and fatal bleeding (0.2 vs. 0.5 %; p = 0.003). As there is discussion on the most appropriate statistical method to evaluate results of non-inferiority trials [16, 17], results based on the intention-to-treat population are also presented. Baseline event rates were obtained from the warfarin arm of the trial and converted into quarterly rates for use in the modelling analysis as described by Briggs et al. [18]. Relative risks of events from ROCKET AF for rivaroxaban were applied to these event rates observed with warfarin. For example, the baseline risk of ischaemic stroke was 1.42 % per year in the warfarin arm of the study, which was converted into a quarterly rate of 0.36 % [11]. For rivaroxaban, this rate was multiplied by a relative risk of 0.94, resulting in a quarterly event rate of 0.34 %. Event rates for systemic embolism, bleeding events, and myocardial infarction were derived in an identical manner. Background mortality, based on Belgian life tables [19], and mortality specific to the clinical events were included in the model (Table 2). Estimates for event-related mortality were based on results of the ROCKET AF study, except for the long-term mortality rates following major stroke [2] and myocardial infarction [20] which were obtained from the literature. Patients could transition to the death health state from all other health states. It was assumed there were no event-related case fatalities in the minor stroke, post-minor stroke, CRNM extracranial bleed, post-CRNM and post-major extracranial bleed, and systemic embolism health states. Treatment discontinuation rates for rivaroxaban (8.90 % in the initial and 4.39 % in subsequent cycles) and warfarin (8.00 % in the initial and 4.46 % in subsequent cycles) were also derived from the ROCKET AF trial.
Table 1

Overview clinical input data (95 % CI)

Event (source)

Baseline risk [%] (3 months)

RR rivaroxaban vs. warfarin

Ischemic stroke [11]

0.36 (0.27–0.45 %)

0.94 (0.75– 1.17)

 Of which major [31]

59.00 (41.84–62.66 %)

 Of which minor

41.00 (37.34–58.16 %)

Systemic embolism [11]

0.05 (0.00–0.76 %)

0.23 (0.09–0.61)

Extracranial CRNM bleed [11]

2.97 (1.79–5.04 %)

1.04 (0.96–1.13)

Extracranial major bleed [11]

0.69 (0.24–1.90 %)

1.14 (0.98–1.33)

Intracranial bleed [11]

0.19 (0.03–1.04 %)

0.67 (0.47–0.93)

Myocardial infarction [11]

0.28 (0.05–1.22 %)

0.81 (0.63–1.06)

CRNM clinically relevant non-major, RR relative risk

Table 2

Mortality rates (95 % CI)

Health state (source)

Event-related mortality rate per 3-month cycle [%]

Major stroke [32]

12.6 (9.4–15.7 %)

Post-major stroke [2, 32]

2.63 (0.91–13.50 %)

Minor stroke

N/Aa

Systemic embolism

N/Aa

Major extracranial bleed [32]

1.55 (1.16–1.94 %)

Intracranial bleed [32]

38.85 (29.14–48.56 %)

Post-intracranial bleed [32]

2.63 (0.91–13.5 %)b

Myocardial infarction [32]

9.69 (7.27–12.11 %)

Post-myocardial infarction [20, 32]

2.68 (0–6.75 %)

N/A not applicable

aIt is assumed minor stroke and systemic embolism have a case-fatality of 0 % and thus mortality rate is equal to that in the general population

bAssumed identical to post-major stroke mortality rate

2.3 Drug and Event Costs

Three relevant cost categories were identified: drug acquisition costs, drug administration/monitoring costs, and events costs (Table 3; Online Resource 1). Based on the market shares and pack sizes of the brands that are locally available, a weighted average drug cost of €0.31 and €0.07 was estimated for VKAs and aspirin, respectively. For rivaroxaban, an average cost of €2.70 per tablet was assumed. When patients are initiated on warfarin therapy, it is recommended that they visit their physician regularly to make the dose adjustments required to maintain the target INR of 2.5 (typical target range is 2.0–3.0). Based on a report of the Belgian health care knowledge centre (KCE), it was assumed that these patients have 15 general practitioner (GP) visits (€29 per visit) and INR laboratory tests (€15.8 per test) per year, or 3.75 per Markov cycle [21]. For aspirin and rivaroxaban, the model assumes that patients would visit their GP two times per year (range 0–8 GP visits) as no monitoring is required for these therapies. At the time the present pharmacoeconomic evaluation was prepared for submission to local reimbursement authorities, costs were inflated to the year 2010 using the appropriate annual Health Index figures as recommended by the Belgian KCE guidelines [22].
Table 3

Overview of drug, monitoring, and event costs [33, 34; Online Resource 1]

Item

Drug costs (per tablet) [€]

Consultatione and INR monitoring costs (per visit) [€]

Rivaroxabana

2.70

29.08

Vitamin K antagonistb

0.31

44.85

Aspirinb

0.07

29.08

Eventc

Acute (per event) [€]

Rehabilitationf (per event) [€]

Long-term follow-up (per 3 months) [€]

Minor stroke

5,946

3,204

244

Major stroke

12,247

17,734

2,216

Systemic embolism

5,124

CRNM extracanial bleed

23

Major extracanial bleed

3,510

Intracranial bleedd

7,699

17,734

2,216

Myocardial infarction

7,891

CRNM clinically relevant non-major, INR international normalized ratio

aAssuming 5 and 95 % of tablets from the 28- (€98.82) and 98-tablet (€260.23) drug packages sizes, respectively

bBased on market share and prices of locally available brands

cThe range of event costs tested in sensitivity analyses was ±25 % of the mean

dCosts of rehabilitation and long-term follow-up were assumed identical, as for major stroke

eIncludes home consultations

fBased on unpublished results, (Putman K, personal communication)

2.4 Health-Related Outcomes

A systematic search was performed to identify health state utility values in AF, stroke, post-stroke, embolism, myocardial infarction, and bleeding events occurring in a non-valvular AF population. The baseline utility for an untreated AF patient aged 73 years was set at 0.799 (Table 4). Utility scores specific to Belgium were not identified during the search. Although it is generally accepted that the need for constant monitoring can adversely affect the quality of life [23, 24, 25], a disutility for warfarin treatment was not applied in the base-case analysis. Table 4 shows the health state utility values and ranges used in the analysis.
Table 4

Overview of utility values (range)

Description

Currently value in the model

Distribution (SD)

Reference

Population

Country

Mean

Range

Stable—not on therapy

0.799

0.635–1

Beta (a = 14.0, b = 3.5)

Dagres et al. [35]

Patients with atrial fibrillation enrolled in the Euro Heart Survey on Atrial Fibrillation, mean age 67 years

Europe

Stable—on warfarin therapy

0.799

0.635–1

N/A

Dagres et al. [35]

Patients with atrial fibrillation enrolled in the Euro Heart Survey on Atrial Fibrillation, mean age 67 years

Europe

Utility decrement used for warfarin

1.000

0.920–1

N/A

Robinson et al. [36]

Patients with atrial fibrillation, male and female, mean age 73 years

UK

Stable—on other therapy

0.799

0.635–1

N/A

Assumed = not on therapy

N/A

N/A

Stable—initiating warfarin therapy

0.799

0.635–1

N/A

Assumed = stable on warfarin

N/A

N/A

Utility decrement used for initiating warfarin

1.000

0.920–1

N/A

Robinson et al. [36]

Patients with atrial fibrillation, male and female, mean age 73 years

UK

Embolic events

 Minor stroke

0.641

0.550–0.660

Beta (a = 187, b = 105)

Robinson et al. [36]

Patients with atrial fibrillation, male and female, mean age 73 years

UK

 Post-minor stroke

0.727

0.538–0.772

Beta (a = 40, b = 15)

Hallan et al. [37]

Stroke survivors, mean age 65 years

Norway

 Major stroke

0.189

0.142–0.236

Beta (a = 50, b = 213)

Robinson et al. [36]

Patients with atrial fibrillation, male and female, mean age 73 years

UK

 Post-major stroke

0.487

0.078–0.710

Beta (a = 4.2, b = 4.4)

Hallan et al. [37]

Stroke survivors, mean age 65 years

Norway

 Systemic embolism

0.679

0.660–0.692

Beta (a = 2251, b = 1061)

Sullivan et al. [38]

Patients with systemic embolic event (ICD-9 444)

US

Bleeding events

 Minor bleed

0.796

0.794–0.789

Beta (a = 34, b = 9)

Sullivan et al. [38]

Patients with systemic embolic event (ICD-9 444)

US

 Major bleed

0.618

0.590–0.645

Beta (a = 762, b = 470)

Sullivan et al. [38]

Patients with systemic embolic event (ICD-9 444)

US

 Intracranial bleed

0.600

0.020–0.635

Beta (a = 1.7 b = 1.1)

Lenert and Soetikno [39]

Deep venous thrombosis, 20–40 for female volunteers

US

 Post-intracranial bleed

0.740

0.078–0.772

Beta (a = 3.8, b = 1.3)

Haacke et al. [40]

Patients with an ischemic, transient ischemic or hemorrhagic stroke, mean age 74.6 years

Germany

Myocardial infarction events

 Myocardial infarction

0.667

0.501–0.799

Beta (a = 25, b = 12)

Robinson et al. [42]

Patients with acute myocardial infarction

UK

 Post-myocardial infarction

0.703

0.528–0.799

Beta (a = 30, b = 13)

Sanders et al. [41]

Patients with past myocardial infarction who did not have sustained ventricular arrhythmia

US

 Death

0.000

0

N/A

Definition

N/A

N/A

ICD International Classification of Diseases, N/A not applicable

2.5 Analysis

The model’s primary outcomes were the number of life-years, quality-adjusted life-years (QALYs), and life-threatening events per patient. In the base-case cost-effectiveness analysis, an ICER was calculated as the difference in costs divided by the difference in outcomes associated with the two treatments. In accordance with local guidelines, future costs were discounted at a rate of 3 %, and future outcomes were discounted at a rate of 1.5 % [22]. In order to fully incorporate the costs and outcomes of AF, the time horizon was set to describe the lifetime of treated patients. A one-way sensitivity analysis and a probabilistic sensitivity analysis (PSA) were performed to evaluate the impact a change in input variables may have on the model’s results. In these analyses, a beta distribution was used for model transition probabilities (event rates) and utility parameters, while relative risk parameters and costs were assumed to have a log-normal distribution, and a gamma distribution was used for resource use [18]. Base-case estimates were adjusted based on 95 % CIs from the analysis of the ROCKET AF trial. Alternatively, point estimates for costs varied by 25 %, which was considered sufficient variation to capture relevant uncertainty. Both the development and the adaptation of this model to the Belgian environment were validated by a number of leading clinicians and health economists. During the validation process, the model’s structure, logic, input data, key assumptions, mathematical steps and functionalities were thoroughly tested.

3 Results

3.1 Base-Case Analysis

In the base-case analysis, rivaroxaban treatment was associated with fewer ischemic strokes and systemic embolisms (0.308 vs. 0.321 events per patient), intracranial bleeds (0.048 vs. 0.063), and myocardial infarctions (0.082 vs. 0.095) compared with warfarin treatment. Consequently, patients treated with rivaroxaban gained more QALYs (8.213 vs. 8.119) and life-years (10.621 vs. 10.510). Over a lifetime time horizon, rivaroxaban treatment led to a reduction of 0.042 life-threatening events per patient, an increase of 0.094 QALYs and 0.111 life-years compared with warfarin treatment. This resulted in an ICER of €8,809 per QALY or €7,493 per life-year gained (Table 5). In a secondary analysis, using clinical data of ROCKET AF’s intention-to-treat population, the ICER was determined at €14,970 per QALY and €11,897 per life-year gained.
Table 5

Cost-effectiveness results and events avoided over the lifetime of patients

Events per 1,000 patients

Rivaroxaban

Warfarin

Difference

Ischemic strokes and systemic embolisms

308

321

−13

Intracranial bleedings

48

63

−16

Myocardial infarctions

82

95

−13

Cost and effectiveness results per patient

 Life-years

10.621

10.510

0.111

 QALY

8.213

8.119

0.094

 Costs (€)

18,695

17,867

828

 Incremental cost-effectiveness ratio (€)

8,809 per QALY gained

QALY quality-adjusted life-years

3.2 Sensitivity Analysis

Results from the one-way sensitivity analysis indicated that the relative risk of rivaroxaban vs. warfarin for stroke, the number of GP/monitoring visits, baseline intracranial bleed rate, and the treatment discontinuation rates were the main drivers of the cost-effectiveness analysis (Fig. 2). While, for example, the ICER was estimated at €5,193 per QALY gained should a patient on rivaroxaban no longer need to visit a physician, it would be around €19,659 per QALY if eight GP visits are required annually. Results from the PSA, based on 10,000 iterations, are presented in Fig. 3 and suggest that rivaroxaban is cost-effective compared with warfarin therapy in 66, 79, and 87 % of cases if a willingness-to-pay threshold of €10,000, €20,000 or €35,000 per additional QALY were to be considered, respectively.
Fig. 2

Tornado diagram showing the main drivers (variables and sensitivity ranges) of the incremental cost-effectiveness ratio (ICER)

Fig. 3

Cost-effectiveness acceptability curve

4 Discussion

The above-mentioned results suggest that, in the Belgian healthcare setting, rivaroxaban is a cost-effective alternative to warfarin for the prevention of stroke in AF patients. The incremental cost of rivaroxaban over warfarin was calculated to be €828 over the patient’s lifetime in the base-case analysis. As warfarin is an off-patent drug, its drug acquisition costs are lower than these of novel innovative drugs such as rivaroxaban. This difference, however, was largely compensated by the decrease in costs related to monitoring and treatment of events. At the same time, the incremental health gain was estimated at a value close to 0.09 QALYs. These figures generate an ICER of approximately €8,809/QALY gained. Per 1,000 patients treated with rivaroxaban, an estimated 42 life-threatening events would be avoided.

One-way sensitivity analysis showed that only two variables were able to drive the ICER beyond a value of €25,000 per QALY. First, the ICER was most sensitive to the relative risk of ischemic stroke for rivaroxaban, indicating that the new treatment may not be cost-effective if it were to be associated with more strokes than warfarin. Results from the ROCKET AF trial, however, suggest that rivaroxaban (149 cases in 7,061 patients) is not less effective than warfarin (161 cases in 7,082 patients) in preventing ischemic strokes. Secondly, a higher cost of warfarin monitoring driven by more frequent visits during the maintenance phase yields a lower ICER. As its predictable anticoagulant effect makes routine monitoring redundant, patients on rivaroxaban will need to visit their GP much less frequently. Based on a report issued by the Belgian KCE [21], we have accepted there would be 15 dose monitoring/adjustment visits per year for warfarin and assumed there would be 2 for rivaroxaban. It was considered likely that the additional, regular clinical attention patients receive from their physician, independent of dose monitoring, would be comparable in both groups.

In addition, the PSA showed that the likelihood of rivaroxaban being cost-effective or even cost saving is very high. Taken together, the results of the deterministic and PSAs thus strongly support the conclusion that rivaroxaban is a cost-effective alternative to warfarin. This is in line with earlier findings from a model developed by Lee and colleagues, which already suggested that rivaroxaban therapy was cost-effective versus adjusted-dose warfarin for stroke prevention in AF in the US healthcare setting [26].

As any economic model, the present analysis has some limitations. One of the limitations was the use of a cohort Markov model for the cost-effectiveness analysis, which is limited in tracking the patient’s history. For example, the risk of a second stroke is elevated over the first stroke, however this was not incorporated in the model. Another limitation of the model is that no Belgian-specific utilities could be found. However, the international values that were identified and used in the model are likely to be representative for the Belgian population because all the utility values were obtained from either a European country or the US, and from a patient population that corresponds to the Belgian population treated for stroke prevention in atrial fibrillation (SPAF) (Table 4). Moreover, it should be noted that the ICERs were not very sensitive to changes in utility values, so this limitation would only have a minimal impact on the overall results.

A Belgian health economic study for dabigatran versus warfarin resulted also in dabigatran being considered cost-effective [27], but a direct comparison between rivaroxaban and dabigatran is not possible because there are no head-to-head trials. An indirect comparison is possible [28] but not robust because of the significant differences in the study population and study design of ROCKET AF, RE-LY and ARISTOTLE. A systematic review between the three NOACs (rivaroxaban, dabigatran, apixaban) concluded that NOACs are cost-effective but the lack of head-to-head trials and the heterogeneous characteristics of underlying trials and modelling methods make it difficult to determine the most cost-effective agent [29].

Its predictable anticoagulant effects and low propensity for drug interactions gives rivaroxaban not only an economical advantage but also a major clinical advantage over VKA therapy. Because of the challenges that are associated with warfarin therapy, many Belgian patients with moderate to high risk (CHADS2 score ≥2) are currently being treated with aspirin (24 %) or receive no prophylaxis at all (25 %). Moreover, not all patients receiving warfarin therapy may actually get optimal anticoagulation. In fact, a cross-sectional study involving 66 general practices in Belgium showed that only 69 % of the day values obtained over a period of 6 months fell within a target range of 0.75 INR units (1.75–3.25) [30]. In the ROCKET AF trial, however, the target range was lower (0.5 INR units; 2.0–3.0) and, consistent with this, a lower proportion of the day values (55 %) fell within the INR target range. The lower proportion of day values in the trial is likely due to the lower INR target range and can also be due to the difference in performance level of warfarin in the trial compared with real life. Since the data from the trial were used in the model, the proportion of patients who receive optimal anticoagulation therapy with warfarin might have been slightly underestimated. If that is true, this affected the ICER in favour of rivaroxaban, although this is difficult to ascertain given the difference in INR target range. Both VKA-treated and untreated patients may thus remain at high risk for stroke. In addition, the simple dosing regimen of rivaroxaban (oral, once daily) may help patients adhere to therapy, which in real life could lead to more patients reaching optimum coagulation with rivaroxaban, thereby reducing the burden of AF-related stroke.

5 Conclusion

The present analysis suggests that rivaroxaban is a cost-effective alternative to warfarin therapy for the prevention of stroke in patients with AF in the Belgian healthcare setting.

Notes

Acknowledgements

The authors would like to acknowledge Dr. Koen Putman for allowing us to use his unpublished results in our cost calculations.

This study was supported by Bayer HealthCare Pharmaceuticals. Mrs. Mimi De Ruyck, Mrs. Petra Faes, Mr. Stefaan Vansieleghem and Mr. Thomas Evers are employees of Bayer HealthCare Pharmaceuticals. Mrs De Ruyck is the author responsible for the overall content of this publication. Mr. Joris Kleintjens, Mrs. Xiao Li, and Mr. Ömer Saka were employees of Deloitte and provided consultant services to Bayer HealthCare. Ms. Yumi Asukai is an employee of IMS Health, which has received consulting fees from Bayer Healthcare. Prof. Steven Simoens, Prof. Vincent Thijs, Prof. Ernst Rietzschel, and Dr. Marnix Goethals acted as consultants to Bayer Healthcare with respect to this study.

Ms. Asukai and Mr. Evers designed the structure of and developed the global economic model. Mr. Kleintjens and Mrs. Li collected local information regarding costs, resource consumption, and utility values, adapted the model to the Belgian perspective and led the writing effort. Dr. Thijs, Dr. Rietzschel, and Dr. Goethals provided input from a Belgian perspective on clinical input data, key assumptions, and the local standard of care. Dr. Simoens was responsible for quality control of the local cost-effectiveness evaluation. Mr. Vansieleghem and Mrs. Faes conducted drug cost calculations, and contributed to the interpretation of results and writing of the manuscript. Mrs. De Ruyck and Mr. Saka coordinated the study and contributed to the interpretation of results.

Supplementary material

40273_2013_87_MOESM1_ESM.docx (34 kb)
Supplementary material 1 (DOCX 33 kb)

References

  1. 1.
    Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly: the Framingham Study. Arch Intern Med. 1987;147:1561–4.PubMedCrossRefGoogle Scholar
  2. 2.
    Marini C, De Santis F, Sacco S, et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke. 2005;36:1115–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Strong K, Mathers C, Bonita R. Preventing stroke: saving lives around the world. Lancet Neurol. 2007;6:182–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Mackay J, Menash GA, Greenlund K. The atlas of heart disease and stroke. Geneva: World Health Organization; 2004.Google Scholar
  5. 5.
    Devroey D, Van Casteren V, Buntinx F. Registration of stroke through the Belgian sentinel network and factors influencing stroke mortality. Cerebrovasc Dis. 2003;16:272–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Camm AJ, Kirchhof P, Lip GYH, et al. Guidelines for the management of atrial fibriliation. The Task Force for the Management of Atrial Fibrilation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369–429.PubMedCrossRefGoogle Scholar
  7. 7.
    British Committee for Standards in Haematology. Guidelines on oral anticoagulation: third edition. Br J Haematol. 1998;101:374–87.CrossRefGoogle Scholar
  8. 8.
    Bayer HealthCare. Data on file: Cegedim report 2010.Google Scholar
  9. 9.
    Evers T, O’Neil WM, Ogilvie IM, et al. PCV144—Stroke prevention in patients with atrial fibrillation: inappropriate anticoagulation and poor INR control. Value Health. 2011;14:A390.CrossRefGoogle Scholar
  10. 10.
    Ansell J, Hirsch J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists. Chest. 2008;133(suppl):S160–98.CrossRefGoogle Scholar
  11. 11.
    Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91.PubMedCrossRefGoogle Scholar
  12. 12.
    Stuart J, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51.CrossRefGoogle Scholar
  13. 13.
    Granger B, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92.PubMedCrossRefGoogle Scholar
  14. 14.
    Camm AJ, Lip GYH, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Eur Heart J. 2012;33:2719–47.PubMedCrossRefGoogle Scholar
  15. 15.
    ROCKET AF Study Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J. 2010;159:340–7.Google Scholar
  16. 16.
    Sanchez MM, Chen X. Choosing the analysis population in non-inferiority studies: per protocol or intent-to-treat. Stat Med. 2006;25:1169–81.CrossRefGoogle Scholar
  17. 17.
    US Department of Health and Human Services. Guidance for industry: non-inferiority clinical trials (draft guidance). Center for Biologics Evaluation and Research (CBER), 2010.Google Scholar
  18. 18.
    Briggs AHE, Claxton K, Sculpher M. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006.Google Scholar
  19. 19.
    Federal Public Service Economy, SMEs, Self-Employed and Energy. Life tables Belgium 1998–2009. [Online]. http://statbel.fgov.be/nl/modules/publications/statistiques/bevolking/downloads/bevolking_sterftetafels.jsp. Accessed 8 Jan 2013.
  20. 20.
    Hoit BD, Gilpin EA, Henninh H, et al. Myocardial infarction in young patients: an analysis by age subsets. Circulation. 1986;74:712–21.PubMedCrossRefGoogle Scholar
  21. 21.
    Gailly J, Gerkens S, Van Den Bruel A, et al. Use of point-of care devices in patients with oral anticoagulation: a Health Technology Assessment. Belgian Health Care Knowledge Centre. Report number: 117C, 2009.Google Scholar
  22. 22.
    Cleemput I, Van Wilder P, Vrijens F, et al. Guidelines for pharmacoeconomic evaluations in Belgium. Belgian Health Care Knowledge Centre. Report number: 78C, 2008.Google Scholar
  23. 23.
    Protheroe J, Fahey T, Montgomery AA, et al. The impact of patients’ preferences on the treatment of atrial fibrillation: observational study of patient based decision analysis. BMJ. 2000;320:1380–4.PubMedCrossRefGoogle Scholar
  24. 24.
    Gage BF, Cardinalli AB, Owens DK. The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Arch Intern Med. 1996;156:1829–36.PubMedCrossRefGoogle Scholar
  25. 25.
    National Institute for Health and Clinical Excellence. Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation: NICE technology appraisal guidance 256. Report number: TA256, 2012.Google Scholar
  26. 26.
    Lee S, Anglade MW, Pisacane R, et al. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation. Am J Cardiol. 2012;110:845–51.PubMedCrossRefGoogle Scholar
  27. 27.
    Wouters et al. Cost-effectiveness of dabigatran etexilate in the prevention of stroke and systemic embolism in patients with atrial fibrillation in Belgium. J Med Econ. Epub 2013 Jan 22Google Scholar
  28. 28.
    HAS, Department of Medecines Assessment. Indirect comparisons methods and validity [Online] Available from: www.has-sante.fr. 2009; July:35.
  29. 29.
    Limone et al. Novel anticoagulants for stroke prevention in atrial fibrillation: a systematic review of cost-effectiveness models. PLOS One. 2013;8(4):e62183.Google Scholar
  30. 30.
    Claes N. Quality of oral anticoagulation in patients with atrial fibrillation: a cross-sectional study in general practice. Eur J Gen Pract. 2006;12:163–8.CrossRefGoogle Scholar
  31. 31.
    Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. New Engl J Med. 2003;349:1019–26.PubMedCrossRefGoogle Scholar
  32. 32.
    Bayer Plc. Submission to National Institute for Health and Clinical Excellence: Single Technology Appraisal (STA) of Rivaroxaban (Xarelto®). 2011.Google Scholar
  33. 33.
    RIZIV/INAMI. Nomenclature codes 101010, 101032, 101076, 103110, 103132, 592815, 592830, 554573. [Online]. http://www.inami.fgov.be/homefr.htm. Accessed August 2011.
  34. 34.
    RIZIV/INAMI. APR DRG codes 045 and 813 - nomenclature codes 460821, 591603, 598021, 598043, 598146, 700000 766065, 766264, and 799621. [Online]. Available from: http://www.inami.fgov.be/homefr.htm. Accessed August 2011.
  35. 35.
    Dagres N, Nieuwlaat R, Vardas PE, et al. Gender-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Heart Survey on Atrial Fibrillation. J Am Coll Cardiol. 2007;49:572–7.PubMedCrossRefGoogle Scholar
  36. 36.
    Robinson A, Thomson R, Parkin D, et al. How patients with atrial fibrillation value different health outcomes: a standard gamble study. J Health Serv Res Policy. 2001;6:92–8.PubMedCrossRefGoogle Scholar
  37. 37.
    Hallan S, Asberg A, Indredavik B, et al. Quality of life after cerebrovascular stroke: a systematic study of patients’ preferences for different functional outcomes. J Intern Med. 1999;246:309–16.PubMedCrossRefGoogle Scholar
  38. 38.
    Sullivan PW, Arant TW, Ellis SL, et al. The cost-effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk for stroke in the US. Pharmacoeconomics. 2006;24:1021–33.PubMedCrossRefGoogle Scholar
  39. 39.
    Lenert LA, Soetikno RM. Automated computer interviews to elicit utilities: potential applications in the treatment of deep venous thrombosis. J Am Med Inform Assoc. 1997;4:49–56.PubMedCrossRefGoogle Scholar
  40. 40.
    Haacke C, Althaus A, Spottke A, et al. Long-term outcome after stroke: evaluating health-related quality of life using utility measurements. Stroke. 2006;37:193–8.PubMedCrossRefGoogle Scholar
  41. 41.
    Sanders GD, Hlatky MA, Every NR, et al. Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction. Ann Intern Med. 2001;135:870–83.PubMedCrossRefGoogle Scholar
  42. 42.
    Robinson MB, Thompson E, Black NA. A model for estimating the cost-utility of clinical audit. The example of thrombolysis for suspected acute myocardial infarction. Int J Technol Assess Health Care. 1998;14:161–71.PubMedCrossRefGoogle Scholar

Copyright information

© The Author(s) 2013

Open AccessThis article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

Authors and Affiliations

  • Joris Kleintjens
    • 1
  • Xiao Li
    • 1
  • Steven Simoens
    • 2
  • Vincent Thijs
    • 3
    • 4
    • 5
  • Marnix Goethals
    • 6
  • Ernst R. Rietzschel
    • 7
    • 8
  • Yumi Asukai
    • 9
  • Ömer Saka
    • 1
  • Thomas Evers
    • 10
  • Petra Faes
    • 11
  • Stefaan Vansieleghem
    • 11
  • Mimi De Ruyck
    • 11
  1. 1.Deloitte Health Economics and Outcomes Research GroupBrusselsBelgium
  2. 2.Department of Pharmaceutical and Pharmacological SciencesKU LeuvenLeuvenBelgium
  3. 3.Laboratory of NeurobiologyVesalius Research Center, VIBLeuvenBelgium
  4. 4.Experimental Neurology (Department of Neurosciences) and Leuven Research Institute for Neuroscience and Disease (LIND)University of Leuven (KU Leuven)LeuvenBelgium
  5. 5.Department of NeurologyUniversity Hospitals LeuvenLeuvenBelgium
  6. 6.Mariaziekenhuis Noord-LimburgOverpeltBelgium
  7. 7.Department of Internal Medicine (Cardiovascular Diseases), Faculty of Medicine and Health SciencesGhent University and Ghent University HospitalGhentBelgium
  8. 8.Department of Public Health, Faculty of Medicine and Health SciencesGhent University and Ghent University HospitalGhentBelgium
  9. 9.IMS HealthLondonUK
  10. 10.Global Market Access/HEORWuppertalGermany
  11. 11.Market Access DepartmentBayer HealthCareDiegem (Machelen)Belgium

Personalised recommendations